NFKB1 and depressive symptom measurement: These processes can disrupt the blood-brain barrier, allowing inflammatory factors to enter the CNS and subsequently activate neuroglia through various signaling pathways such as NF-κB and cholinergic mechanisms, ultimately promoting the development of depression (Han et al., 2022).